Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!
Pyrazole alcohol compound, pharmaceutical composition thereof and application thereof to drugs
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of compounds and solvates, applied in the field of medicinal chemistry, can solve the problems of application limitation, poor stability of drug metabolism, accumulation of poisoning, etc.
Active Publication Date: 2018-09-21
GUIZHOU MEDICAL UNIV
View PDF3 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Ligustrazine has poor fat solubility and low bioavailability, which leads to its fast metabolism, short half-life, and poor drugmetabolism stability. In order to maintain an effective drug treatment concentration, it must be administered frequently clinically, which is easy to cause accumulation and poisoning, making its application restricted. certain limit
Edaravone is an antioxidant and free radical scavenger, which belongs to a small lipophilic molecule, which can form a high blood-brain barrier passage rate in the human body, and can prevent or treat neurons by protecting neurons in patients. The effect of treating cerebral apoplexy, but Edaravone has poor water solubility and is easy to oxidize in aqueous solution. In order to increase its water solubility and stability, it is often necessary to add alkaline substances and antioxidant substances in the preparation. The addition of these substances may give Patient causing unwanted side effects
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0153] Example 1. 3-Methyl-1-(3,5,6-trimethylpyrazin-2-yl)-1H-pyrrol-5-ol (Compound 1): Yield 70.6%, oily liquid. 1 HNMR (500MHz, CDCl 3 )δ: 1 H NMR (400MHz, DMSO-d 6 ):δ:2.30(s,3H),2.51-2.54(m,9H),5.90(s,1H),12.2(s,1H,OH); HRMS(ESI) calculated value C 11 h 15 N 4 O[M+H] + :219.1246, measured value: 219.1247.
Embodiment 2
[0154] Example 2. 3-Ethyl-1-(3,5,6-trimethylpyrazin-2-yl)-1H-pyrrol-5-ol (compound 2): yield 65.6%, oily liquid. 1 HNMR (400MHz,d 6 -DMSO)δ: 1.14 (t, 3H, J=7.6Hz), 2.29 (s, 3H), 2.44-2.50 (m, 8H), 5.29 (s, 1H), 11.16 (s, 1H); HRMS (ESI ) Calculated value C 12 h 17 N 4 O[M+H] + :233.1402, measured value: 233.1396.
Embodiment 3
[0155] Example 3.3-tert-amyl-1-(3,5,6-trimethylpyrazin-2-yl)-1H-pyrrol-5-ol (compound 3): yield 49.8%, white solid, m.p.167 -168°C. 1 HNMR (400MHz,d 6 -DMSO) δ: 0.70(t, J=7.2Hz, 3H), 1.15(s, 6H), 1.49-1.54(m, 2H), 2.20(s, 3H), 2.44(s, 3H), 2.49(s ,3H),5.34(s,1H),11.07(s,1H); 13 CNMR (100MHz, d 6 -DMSO)δ: 9.1, 19.2, 20.8, 21.2, 27.1, 35.3, 35.5, 83.3, 142.7, 146.7, 148.4, 151.5, 153.5, 159.7; HRMS (ESI) calculated value C 15 h 23 N 4 o 2 [M+H] + : 275.1794, measured value 275.1789.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a 1-(3,5,6-trimethyl pyrazine-2-yl)-5-pyrazolealcohol compound, a tautomer thereof, a pharmaceutical composition thereof and application thereof to drugs. The 1-(3,5,6-trimethyl pyrazine-2-yl)-5-pyrazolealcohol compound has double effects of resisting platelet aggregation and protecting nerve cells, and comprises a compound as shown in the formula (I), a tautomer (Ia) thereof, or a stereoisomer, a geometrical isomer, a hydrate or a solvate thereof, or a pharmaceutically acceptable salt or prodrug as shown in the description. The 1-(3,5,6-trimethyl pyrazine-2-yl)-5-pyrazolealcohol compound and the pharmaceutical composition thereof provided by the invention can be used for preparing drugs for prevention and / or treatment and / or auxiliary treatment of cerebral apoplexy, cardiovascular and cerebrovascular diseases, senile dementia and complications thereof caused by thrombosis and excessive free radicals.
Description
field of invention [0001] The invention belongs to the technical field of medicinal chemistry, and specifically relates to 1-(3,5,6-trimethylpyrazin-2-yl)-5-pyrazolol compounds, tautomers thereof, and pharmaceutical compositions thereof and applications in medicine. Background of the invention [0002] Stroke is a refractorydisease that seriously endangers the safety of human life and is characterized by high morbidity, disability and mortality. The survey results of the World Health Organization show that the incidence of stroke in China ranks first in the world, twice as high as that in the United States, and the incidence of cerebrovascular diseases in my country has increased significantly in recent years, with an annual growth rate of 9%. It is estimated that by 2030 In my country, 4 million people will die of stroke every year. Therefore, stroke has become an important disease affecting the health of Chinese people, and it is urgent to carry out the prevention and tr...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.